Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Provention Bio
Red Bank, New Jersey, United Statesproventionbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TZIELD (teplizumab-mzwv) was approved in the United States as the first and only therapy to delay the onset of Stage 3 T1D in adults and pediatric patients aged 8 years and older with Stage 2 T1D[6]. The company's lead product TZIELD is currently being evaluated in a Phase 3 trial (PROTECT) for treatment of newly diagnosed clinical T1D with results expected in the second half of 2023[6].
- Therapeutic areas
- GastroenterologyEndocrinologyImmunology
- Modalities
- Monoclonal antibodiesvaccines
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Provention Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Provention Bio.